Your browser doesn't support javascript.
loading
Radiotherapy as a tool for the treatment of Cushing's disease.
Castinetti, Frederic; Brue, Thierry; Ragnarsson, Oskar.
Afiliação
  • Castinetti F; Aix-Marseille Université, Institut National de la Santé et de la Recherche Médicale, Marseille Medical Genetics, Marseille, France.
  • Brue T; Department of Endocrinology, Assistance Publique-Hôpitaux de Marseille, Hôpital de la Conception, Centre de Référence des Maladies Rares de l'hypophyse, Marseille, France.
  • Ragnarsson O; Aix-Marseille Université, Institut National de la Santé et de la Recherche Médicale, Marseille Medical Genetics, Marseille, France.
Eur J Endocrinol ; 180(5): D9-D18, 2019 May 01.
Article em En | MEDLINE | ID: mdl-30970325
ABSTRACT
Treatment of Cushing's disease (CD) is one of the most challenging tasks in endocrinology. The first-line treatment, transsphenoidal pituitary surgery, is associated with a high failure rate and a high prevalence of recurrence. Re-operation is associated with an even higher rate of a failure and recurrence. There are three main second-line treatments for CD - pituitary radiation therapy (RT), bilateral adrenalectomy and chronic cortisol-lowering medical treatment. All these treatments have their limitations. While bilateral adrenalectomy provides permanent cure of the hypercortisolism in all patients, the unavoidable chronic adrenal insufficiency and the risk of development of Nelson syndrome are of concern. Chronic cortisol-lowering medical treatment is not efficient in all patients and side effects are often a limiting factor. RT is efficient for approximately two-thirds of all patients with CD. However, the high prevalence of pituitary insufficiency is of concern as well as potential optic nerve damage, development of cerebrovascular disease and secondary brain tumours. Thus, when it comes to decide appropriate treatment for patients with CD, who have either failed to achieve remission with pituitary surgery, or patients with recurrence, the pros and cons of all second-line treatment options must be considered.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Hipersecreção Hipofisária de ACTH Tipo de estudo: Etiology_studies / Risk_factors_studies Limite: Humans Idioma: En Revista: Eur J Endocrinol Ano de publicação: 2019 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Hipersecreção Hipofisária de ACTH Tipo de estudo: Etiology_studies / Risk_factors_studies Limite: Humans Idioma: En Revista: Eur J Endocrinol Ano de publicação: 2019 Tipo de documento: Article